Sunitinib followed by sorafenib or vice versa for metastatic
renal cell carcinoma-data from the Czech registry

J 2012

Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry

BÜCHLER, Tomáš; Radim KLAPKA; B. MELICHAR; Petr BRABEC; Ladislav DUŠEK et al.

Základní údaje

Originální název

Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry

Autoři

BÜCHLER, Tomáš; Radim KLAPKA; B. MELICHAR; Petr BRABEC; Ladislav DUŠEK; Rostislav VYZULA a J. ABRAHAMOVA

Vydání

Annals of Oncology, OXFORD, OXFORD UNIV PRESS, 2012, 0923-7534

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 7.384

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/12:00059259

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1093/annonc/mdr065

UT WoS

000299744400018

Klíčová slova anglicky

renal cell carcinoma; sorafenib; sunitinib

Příznaky

Mezinárodní význam

Změněno: 18. 6. 2012 08:28, Mgr. Michal Petr

Anotace

V originále

Background: Sequential therapy with tyrosine kinase inhibitors (TKIs), sunitinib and sorafenib, is a common treatment choice for patients with advanced/metastatic renal cell carcinoma (mRCC) despite lack of randomised trials. The aim of this retrospective registry-based study was to analyse the outcomes of RCC patients treated with sunitinib-sorafenib or sorafenib-sunitinib sequence. Patients and methods: The Czech database containing information on patients treated for mRCC using targeted agents was used as a source of data for retrospective analysis. There were 138 patients treated with sunitinib-sorafenib sequence and 122 patients treated with sorafenib-sunitinib sequence. Results: Progression-free survival (PFS) was 17.7 months for patients treated with sunitinib-sorafenib sequence and 18.8 months for those receiving sorafenib followed by sunitinib (P = 0.47). Overall survival (OS) at 1 year was 83% [95% confidence interval (CI) 77% to 90%] for patients treated with sunitinib-sorafenib and 84% (95% CI 77% to 91%) for sorafenib-sunitinib patients (P = 0.99). Treatment toxic effects were predictable but a significant proportion of patients (up to 14%-25% for different lines of therapy and used TKI) switched between TKIs or discontinued TKI therapy because of toxicity. Conclusions: In contrast to most of the previously published reports, we have not observed improved PFS or OS for mRCC patients treated with the sorafenib-sunitinib sequence as compared to the sunitinib-sorafenib sequence.

Citovat

BÜCHLER, Tomáš; Radim KLAPKA; B. MELICHAR; Petr BRABEC; Ladislav DUŠEK; Rostislav VYZULA a J. ABRAHAMOVA. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry. Annals of Oncology. OXFORD: OXFORD UNIV PRESS, 2012, roč. 23, č. 2, s. 395-401. ISSN 0923-7534. Dostupné z: https://doi.org/10.1093/annonc/mdr065.

@article{968978,
   author = {Büchler, Tomáš and Klapka, Radim and Melichar, B. and Brabec, Petr and Dušek, Ladislav and Vyzula, Rostislav and Abrahamova, J.},
   article_location = {OXFORD},
   article_number = {2},
   doi = {https://doi.org/10.1093/annonc/mdr065},
   keywords = {renal cell carcinoma; sorafenib; sunitinib},
   language = {eng},
   issn = {0923-7534},
   journal = {Annals of Oncology},
   title = {Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry},
   volume = {23},
   year = {2012}
}

TY  - JOUR
ID  - 968978
AU  - Büchler, Tomáš - Klapka, Radim - Melichar, B. - Brabec, Petr - Dušek, Ladislav - Vyzula, Rostislav - Abrahamova, J.
PY  - 2012
TI  - Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry
JF  - Annals of Oncology
VL  - 23
IS  - 2
SP  - 395-401
EP  - 395-401
PB  - OXFORD UNIV PRESS
SN  - 09237534
KW  - renal cell carcinoma
KW  - sorafenib
KW  - sunitinib
N2  - Background: Sequential therapy with tyrosine kinase inhibitors (TKIs), sunitinib and sorafenib, is a common treatment choice for patients with advanced/metastatic renal cell carcinoma (mRCC) despite lack of randomised trials. The aim of this retrospective registry-based study was to analyse the outcomes of RCC patients treated with sunitinib-sorafenib or sorafenib-sunitinib sequence. Patients and methods: The Czech database containing information on patients treated for mRCC using targeted agents was used as a source of data for retrospective analysis. There were 138 patients treated with sunitinib-sorafenib sequence and 122 patients treated with sorafenib-sunitinib sequence. Results: Progression-free survival (PFS) was 17.7 months for patients treated with sunitinib-sorafenib sequence and 18.8 months for those receiving sorafenib followed by sunitinib (P = 0.47). Overall survival (OS) at 1 year was 83% [95% confidence interval (CI) 77% to 90%] for patients treated with sunitinib-sorafenib and 84% (95% CI 77% to 91%) for sorafenib-sunitinib patients (P = 0.99). Treatment toxic effects were predictable but a significant proportion of patients (up to 14%-25% for different lines of therapy and used TKI) switched between TKIs or discontinued TKI therapy because of toxicity. Conclusions: In contrast to most of the previously published reports, we have not observed improved PFS or OS for mRCC patients treated with the sorafenib-sunitinib sequence as compared to the sunitinib-sorafenib sequence.
ER  -

BÜCHLER, Tomáš; Radim KLAPKA; B. MELICHAR; Petr BRABEC; Ladislav DUŠEK; Rostislav VYZULA a J. ABRAHAMOVA. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry. \textit{Annals of Oncology}. OXFORD: OXFORD UNIV PRESS, 2012, roč.~23, č.~2, s.~395-401. ISSN~0923-7534. Dostupné z: https://doi.org/10.1093/annonc/mdr065.

Přehled o publikaci